AMBS - Most undervalued bio-tech in the market. Read the recent Yahoo news.
Expected to announce a deal soon with Becton Dickinson for its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market.
Company's patented drug, MANF, could be the blockbuster drug of the 21st century. Due diligence.
Current market cap: $29M
Under a dime a share currently.
Follow the company on Twitter: @AmarantusBio .... 8,542 followers
You're on the wrong board AGAIN. Reported for SPAM and ignored AGAIN.
Check out who's on the company's advisory board on the company's website.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is a strong supporter of the company. "The next Amgen in its infancy".
Your reputation precedes you both - why the heck would we listen to you!
To make a substantial profit.
AMBS with a market cap of 29M versus MNKD with a market cap of $2.4 billion.
Which as more upside over the next six months?